Skip to main content
. 2021 Jan 25;40:43. doi: 10.1186/s13046-021-01839-4

Fig. 3.

Fig. 3

Modulation of miR-155 reprograms PGE2 and PGD2 production in human breast cancer cells, by the regulation of three prostaglandin synthases. a Relative PGE2 (left) and PGD2 (right) levels in MDA-MB-436 or Hs-578 T cells in control (in blue) or in miR-155-depleted cells (miRZIP155 in red). b The overexpression of miR-155 (miRH, in yellow) drives increased PGE2 (left) and decreased PGD2 (right) expression in MCF7 cells. c-f Relative RNA expression of Ptges1(c), Ptges2(d), Ptgds(e) and 15-Pgdh(f) in MDA-MB-436, Hs-578 T, and MCF7 cells after knockdown (miRZIP155, in red) or overexpression (miRH155, in yellow) of miR-155. g Western blot analysis of key metabolic enzymes for PGE2/PGD2 homeostasis, after knockdown (miRZIP155) or overexpression (miRH155) of miR-155 in three breast cancer cell lines